November 1, 2024
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse™ makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse™.

In this episode of Med Tech Talks, host Robert Klupacs is joined by Justin Zenanko, co-founder, CEO and president of SynerFuse™, a medical device company based in the United States developing an innovative solution to reduce chronic back pain and improve patient quality of life. 

October 10, 2024
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse™ makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse™.

(Duluth, Minn.) A Duluthian man went from barely able to walk to now moving around pain-free thanks to this new innovative medical technology. SynerFuse is a company made of specialists from the University of Minnesota and the Fairview Health system. They are working towards better and more regular outcomes with spine surgeries.

September 24, 2024
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse™ makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse™.

(Eden Prairie, Minn.) In this episode, The Deal Scout podcast host Josh Wilson converses with SynerFuse CEO Justin Zenanko, "a remarkable guest whose journey from a certified public accountant (CPA) to a key player in the medical device industry is nothing short of inspiring... Justin’s transition from a CPA to raising capital for groundbreaking medical technologies is a testament to the power of adaptability and passion."

September 9, 2024
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse™ makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse™.

(Eden Prairie, Minn.) Circuit Breakers is an interview series by Steve Semler of FocalPoint/LearningSim with business leaders in or supporting the tech sector. In the interview, Semler explored how SynerFuse, as a leader in the technology business, “breaks the circuit” of the routine and stays innovative. 

September 9, 2024
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse™ makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse™.

(Eden Prairie, Minn.) In this episode of the "Capitalist Culture" podcast, SynerFuse CEO Justin Zenanko discusses valuable lessons and innovative ideas that host Kip Knippel says are "sure to resonate with investment groups and growth-stage business owners."

August 21, 2024
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse™ makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse™.

(Eden Prairie, Minn.) ORTHOWORLD spoke with SynerFuse CEO Justin Zenanko about the company's technology and next steps.

July 24, 2024
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse™ makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse™.

(Eden Prairie, Minn.) Justin Zenanko CEO & Co-Founder of Synerfuse covers some key points in bringing innovation to the healthcare space in this episode.

July 16, 2024
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse™ makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse™.

(Eden Prairie, Minn.) Justin Zenanko, CEO and co-founder of SynerFuse discusses a groundbreaking technique combining spinal fusion and direct nerve stimulation to treat chronic low back pain, aiming to eliminate the need for postoperative opioids.

June, 2024
The following contains information regarding an investigational product, the safety or effectiveness of which has not been established. This investigational product is not approved by the FDA and is currently being studied under an FDA-approved Investigational Device Exemption study. The product is limited by Federal (U.S.) law to investigational use only. SynerFuse™ makes no claims of safety or effectiveness of the investigational product, and the intent of presenting this information is to convey research and development initiatives underway at SynerFuse™.

(Eden Prairie, Minn.) With 40% of spinal fusion surgeries failing to relieve low back and leg pain, SynerFuse adds neuromodulation to traditional methods in a novel yet intuitive implant.

May 15, 2024
(Eden Prairie, Minn.) Steven Falowski, MD, was named chair of SynerFuse's medical advisory board, and Deepak Reddy, MD was named vice chair.

May 15, 2024 (Eden Prairie, Minn.)
SynerFuse today announced the appointment of Steven Falowski, M.D., FAANS as chair of the company’s Medical Advisory Board and Deepak Reddy, M.D. as vice chair. 

February 1, 2024
(Eden Prairie, Minn.)  Here are six spine surgeons who moved to new practices or added to their titles in January.

January 8, 2024
(Eden Prairie, Minn.) SynerFuse has announced the appointment of Rohan Lall (M Health Fairview Neurosurgery, Princeton, USA) as the company’s chief medical officer. The appointment was effective on 2 January 2024.

January 8, 2024
(Eden Prairie, Minn.) Here are three C-suite leadership moves in the spine and orthopedic space Becker's has reported on since Jan. 3.

January 8, 2024
(Eden Prairie, Minn.) SynerFuse has announced the appointment of Rohan Lall (M Health Fairview Neurosurgery, Princeton, USA) as the company’s chief medical officer. The appointment was effective on 2 January 2024.

January 3, 2024
(Eden Prairie, Minn.) SynerFuse today announced the appointment of Rohan Lall, M.D., as the company’s chief medical officer. Dr. Lall co-developed the patented Electric Transforaminal Lumbar Interbody Fusion (e-TLIF) SynerFuse procedure, which combines fusion with direct nerve stimulation to address chronic low back and leg pain that is unaddressed in traditional spinal fusion surgery.

January 3, 2024
(Eden Prairie, Minn.) Rohan Lall, MD, was named chief medical officer of SynerFuse. Dr. Lall helped develop the company's Electric Transforaminal Lumbar Interbody Fusion procedure, according to a Jan. 3 news release shared with Becker's. 

October 19, 2023 
(Eden Prairie, Minn.) On October 17, 2023, SynerFuse, completed the enrollment of participants in its proof-of-concept study to evaluate the safety and tolerability of the Electric Transforaminal Lumbar Interbody Fusion (e-TLIF™) procedure integrating spinal fusion with direct nerve stimulation, which is designed to treat neuropathic chronic lower-back pain (cLBP).

October 18, 2023
(Eden Prairie, Minn.) SynerFuse™ has announced that it has completed enrollment in its proof-of-concept study to evaluate the safety and tolerability of the Electric Transforaminal Lumbar Interbody Fusion (e-TLIF™) procedure integrating spinal fusion with direct nerve stimulation, which is designed to treat neuropathic chronic low back pain (CLBP).

October 18, 2023
(Eden Prairie, Minn.) SynerFuse™ has announced that it has completed enrollment in its proof-of-concept study to evaluate the safety and tolerability of the Electric Transforaminal Lumbar Interbody Fusion (e-TLIF™) procedure integrating spinal fusion with direct nerve stimulation, which is designed to treat neuropathic chronic low back pain (CLBP).

October 17, 2023
(Eden Prairie, Minn.) SynerFuse completed enrollment in its proof-of-concept study to evaluate the safety and tolerability of the Electric Transforaminal Lumbar Interbody Fusion (e-TLIF) procedure that integrates spinal fusion with direct nerve stimulation, and is designed to treat neuropathic chronic lower back pain.

October 17, 2023
(Eden Prairie, Minn.) SynerFuse™ today announced the completion of enrollment in its proof-of-concept study to evaluate the safety and tolerability of the Electric Transforaminal Lumbar Interbody Fusion (e-TLIF™) procedure integrating spinal fusion with direct nerve stimulation, which is designed to treat neuropathic chronic lower-back pain (cLBP). 

October 17, 2023
(Eden Prairie, Minn.) SynerFuse™ completed enrollment for its proof-of-concept study to evaluate the e-TLIF™ procedure with direct nerve stimulation. So far 15 patients underwent surgery in the proof-of-concept study, according to an Oct. 17 news release.

September 20, 2023
(South Bend, Ind.) A South Bend Orthopedic Surgeon made history over the summer, becoming the first surgeon in [Indiana] to perform a revolutionary new spinal procedure solo, and the first to do it outside of the state of Minnesota. Dr. Deepak Reddy leads the national clinical trial for the SynerFuse™ Procedure, focusing on the safety of combining a spinal fusion with neuromodulation. 

September 5, 2023
(Eden Prairie, Minn.) SynerFuse™ announced today that an independent Data Safety and Monitoring Board (DSMB) met and recommended no changes after review of the first ten implanted subjects in the company’s ongoing proof-of-concept study. 

August 31, 2023
(Eden Prairie, Minn.) SynerFuse™, Inc., announced today that an independent Data Safety and Monitoring Board (DSMB) met and recommended no changes after review of the first ten implanted subjects in the company’s ongoing proof-of-concept study.

August 8, 2023
(Mishawaka, Ind.) Deepak Reddy, MD, of South Bend (Ind.) Orthopedics completed the first solo SynerFuse™ procedure.

July 3, 2023
(Minneapolis, Minn.) A "first-of-its-kind" study is giving a dozen Minnesotans relief from debilitating leg and back pain. Surgeons with M Health Fairview are testing an innovative new procedure, combining two concepts for the very first time as they aim to improve long-term pain relief.

June 29, 2023
(Eden Prairie, Minn.) SynerFuse™ has announced that—for the first time in the world, it claims—a solo spine surgeon has performed the SynerFuse procedure in a two-level spinal fusion patient.

June 29, 2023
(Eden Prairie, Minn.) SynerFuse™ has announced that—for the first time in the world, it claims—a solo spine surgeon has performed the SynerFuse procedure in a two-level spinal fusion patient.

June 27, 2023
(Eden Prairie, Minn.) Justin Zenanko, CEO of SynerFuse™, Inc., a Minnesota-based medical device company, is pleased to announce that for the first time in the world, a solo spine surgeon performed the SynerFuse procedure in a two-level spinal fusion patient. Dr. Rohan Lall performed a two-level spinal fusion procedure and implanted a neurostimulator system in the 10th patient in the proof-of-concept study evaluating the safety and feasibility of this investigational integrated procedure.

June 26, 2023
(Eden Prairie, Minn.) SynerFuse™ announced today the first solo-surgeon two-level SynerFuse procedure. Dr. Rohan Lall performed a two-level spinal fusion procedure and implanted a neurostimulator system in the 10th patient in the proof-of-concept study evaluating the safety and feasibility of this investigational integrated procedure. 

June 9, 2023
(Minneapolis, Minn.) M Health Fairview surgeons performed the first-ever SynerFuse™ procedure, integrating spinal fusion and neuromodulation in a proof-of-concept study aimed at improving long-term pain relief.

April 30, 2023
(Eden Prairie, Minn.) SynerFuse™ has announced that Michael Park (University of Minnesota, Minneapolis, USA)—principal investigator for the company’s investigational device exemption (IDE) proof-of-concept study—presented data from the study’s first eight patients at the 10th annual Minnesota Neuromodulation Symposium (20–21 April, Minneapolis, USA).

April 30, 2023
(Eden Prairie, Minn.) SynerFuse™ has announced that Michael Park (University of Minnesota, Minneapolis, USA)—principal investigator for the company’s investigational device exemption (IDE) proof-of-concept study—presented data from the study’s first eight patients at the 10th annual Minnesota Neuromodulation Symposium (20–21 April, Minneapolis, USA).

April 24, 2023
(Eden Prairie, Minn.) Justin Zenanko, CEO of SynerFuse™, is proud to announce that Michael Park, M.D., associate professor of neurosurgery at the University of Minnesota, SynerFuse IDE Proof of Concept study PI, presented data from the Proof of Concept study's first eight patients at the 10th annual Minnesota Neuromodulation Symposium, April 21, 2023. 

February 24, 2023
(Eden Prairie, Minn.) According to filings with the U.S. Securities and Exchange Commission, SynerFuse™ is raising $25,000,000.00 in new funding. 

February 6, 2023
(Eden Prairie, Minn.) Our most viewed piece in January was an insightful video interview—conducted at DWG Kongress—with Michael Fehlings (Toronto, Canada) on the management of patients with spinal cord injury. There were also some interesting industry announcements in January from Abbott, SI-Bone, Empirical Spine, SynerFuse™ and Surglasses.

January 16, 2023
(Eden Prairie, Minn.) Justin Zenanko, the CEO of SynerFuse™, has announced that—in what the company says is a world-first—a solo spine surgeon has performed the “groundbreaking” SynerFuse™ procedure. Rohan Lall (M Health Fairview, Minneapolis, USA) simultaneously performed both a spinal fixation procedure and implanted a neurostimulator with leads on the eighth patient in the company’s proof-of-concept study, according to a press release.

January 11, 2023
(Eden Prairie, Minn.) Justin Zenanko, CEO of SynerFuse™, Inc., a Minnesota-based medical device company, is pleased to announce that for the first time in the world, a solo spine surgeon performed the groundbreaking SynerFuse™ procedure. Rohan Lall, MD, at once both performed a spinal fixation procedure and implanted a neurostimulator with leads on the eighth patient in the company’s proof-of-concept study.

January 9, 2023
(Eden Prairie, Minn.) SynerFuse™ announced today that for the first time, a solo spine surgeon performed the SynerFuse™ procedure, implanting a spinal fixation device as well as a neurostimulator. Rohan Lall, MD performed the procedure on the eighth patient in the company's proof-of-concept study."

January 9, 2023
(Eden Prairie, Minn.) Justin Zenanko, CEO of SynerFuse™, Inc., a Minnesota-based medical device company, is pleased to announce that for the first time in the world, a solo spine surgeon performed the groundbreaking SynerFuse procedure. Rohan Lall, MD, at once both performed a spinal fixation procedure and implanted a neurostimulator with leads on the eighth patient in the company’s proof-of-concept study.

January 9, 2023
(Eden Prairie, Minn.) Justin Zenanko, the CEO of SynerFuse™, announced today that—in what the company says is a world-first—a solo spine surgeon has performed the “groundbreaking” SynerFuse™ procedure. Rohan Lall (M Health Fairview, Minneapolis, USA) simultaneously performed both a spinal fixation procedure and implanted a neurostimulator with leads on the eighth patient in the company’s proof-of-concept study, according to a press release.

January 9, 2023
(Eden Prairie, Minn.) Rohan Lall, MD, was the first to use SynerFuse's spinal implant in a solo procedure, the medtech company said Nov. 9. Dr. Lall's surgery is the eighth in SynerFuse's proof-of-concept study combining spinal fusion with the implant of a neurostimulator, according to a news release. He has been involved in previous cases as part of the study.

January 9, 2023
(Eden Prairie, Minn.) Justin Zenanko, CEO of SynerFuse™, Inc., is pleased to announce that for the first time in the world, a solo spine surgeon performed the groundbreaking SynerFuse™ procedure. Rohan Lall, MD, at once both performed a spinal fixation procedure and implanted a neurostimulator with leads on the eighth patient in the company’s proof-of-concept study. 

January 5, 2023
(Eden Prairie, Minn.) SynerFuse™ Co-Founder & CEO Justin Zenanko has been recognized as one of the 500 Most Powerful and Influential Leaders in Minnesota in 2022, in the med-tech category by Greenspring Media, an initiative of Minnesota Monthly. 

October 18, 2022
(Eden Prairie, Minn.) SynerFuse™ announced today that an independent Data Safety and Monitoring Board (DSMB) completed its pre-specified safety review of the first five implanted subjects in the company's ongoing proof-of-concept study. 

October 18, 2022
(Eden Prairie, Minn.) SynerFuse™, Inc., announced today that an independent Data Safety and Monitoring Board (DSMB) completed its pre-specified safety review of the first five implanted subjects in the company's ongoing proof-of-concept study.

July 26, 2022
(Minneapolis, Minn.) SynerFuse™ announced today the completion of the fifth procedure in the company's proof-of-concept study. The procedures were performed by Michael C. Park, MD, PhD, and Rohan Lall, MD, at M Health Fairview University of Minnesota Medical Center.

July 26, 2022
(Minneapolis, Minn.) Michael Park, MD, PhD, and Rohan Lall, MD, completed the fifth procedure using the SynerFuse™ spine implant as part of a proof-of-concept study combining spinal fusion with the implant of a neurostimulator.

July 26, 2022
(Minneapolis, Minn.) Justin Zenanko, CEO of SynerFuse™, Inc., a Minneapolis-based medical device company, is pleased to announce completion last week of the company's groundbreaking procedure in a fifth patient in the company's proof-of-concept study. The patients have been implanted by Michael C. Park, MD, PhD, and Rohan Lall, MD, at M Health Fairview University of Minnesota Medical Center. 

July 22, 2022
(Minneapolis, Minn.) Minne Inno — the Business Journal's news outlet focused on the startup scene — is proud to present its fifth installment of the Blazer Awards.

July 8, 2022
(Minneapolis, Minn.) SynerFuse™ CEO Justin Zenanko and his co-founder are out to blaze a trail, one they believe will have an enormous impact on the lives of people living with chronic lower back pain.

June 15, 2022
(Minneapolis, Minn.) Minne Inno named its fifth class of Blazer Awards winners during its virtual Inno on Fire event on Thursday.

June 7, 2022
(Washington, D.C.) Innovations Would Put a Dent in the Opioid Crisis. According to the Centers for Disease Control and Prevention, 841,000 Americans have died of drug overdoses since 1999. In 2019 alone, 49,860 people were killed by opioid-related overdoses — 70.6 percent of all drug overdose deaths. This was before COVID-19, which almost certainly accelerated drug-related suicide and death, though data are not yet available.

May 12, 2022
(Minneapolis, Minn.) Neurosurgeon Named Advisor to Spine Medtech Company

Neurosurgeon Steven Falowski, MD, was named as a strategic adviser to SynerFuse™, a company focused on treating chronic lower back pain.

May 12, 2022
(Minneapolis, Minn.) SynerFuse™, Inc., a Minneapolis-based medical device company, is pleased to announce the addition of Steven M. Falowski, M.D., F.A.A.N.S., as a strategic advisor. Falowski brings clinical, advisory, and board experience to the SynerFuse team.

Spring, 2022
(Minneapolis, Minn.) From robots to software to pain treatment, here are the innovations on our radar for 2022, and the innovators behind them.

February 15, 2022
(Minneapolis, Minn.) SynerFuse™, Inc., a privately held, clinical-stage medical device company focused on the development of a novel neuromodulation therapy concept for the treatment of chronic back pain, today announced that the U.S. Patent & Trademark Office (USPTO) has issued U.S. Patent Number 11,247,046 entitled Methods and Systems for Implanting a Neuromodulation System at a Surgically Open Spinal Treatment Site. The issuance of the ‘046 patent will add to the company’s growing worldwide patent portfolio that currently includes 63 patents and published patent applications.

January 19, 2022
(Minneapolis, Minn.) SynerFuse™ has announced the first implantation in the company’s proof-of-concept study evaluating the safety and tolerability of simultaneously implanting spinal fusion hardware and a dorsal root ganglion (DRG) neurostimulator in patients suffering from chronic lower back pain (CLBP).

January 14, 2022
(Minneapolis, Minn.) SynerFuse™ has announced the first implantation in the company’s proof-of-concept study, which will evaluate the safety and tolerability of simultaneously implanting spinal fusion hardware and a dorsal root ganglion (DRG) neurostimulator in patients suffering from chronic lower back pain.

January 14, 2022 
(Minneapolis, Minn.) SynerFuse™, Inc., a Minneapolis-based medical device company, is pleased to announce the first implantation in the company's proof-of-concept study. The study will evaluate the safety and tolerability of simultaneously implanting spinal fusion hardware and a dorsal root ganglion (DRG) neurostimulator in patients suffering from chronic lower back pain (cLBP). The first patient was implanted by Dr. Michael Park, MD, PhD, and Dr. Rohan Lall, MD, at M Health Fairview University of Minnesota Medical Center. 

January 14, 2022
(Minneapolis, Minn.) A clinical trial is underway testing an implanted device providing electronic stimulation along with spinal fusion surgery to treat chronic lower back pain. SynerFuse™ in Minneapolis, developer of the device and sponsor of the trial at University of Minnesota Medical Center, says surgeons implanted the device in the study’s first participant.

January 13, 2022
(Minneapolis, Minn.) SynerFuse™ announced today the first implantation in the company's proof-of-concept study. The study will evaluate the safety and tolerability of simultaneously implanting spinal fusion hardware and a dorsal root ganglion (DRG) neurostimulator in patients suffering from chronic lower back pain (cLBP).

January 13, 2022
(Minneapolis, Minn.) SynerFuse™, Inc., a Minneapolis-based medical device company, is pleased to announce the first implantation in the company's proof-of-concept study. The study will evaluate the safety and tolerability of simultaneously implanting spinal fusion hardware and a dorsal root ganglion (DRG) neurostimulator in patients suffering from chronic lower back pain (cLBP). The first patient was implanted by Dr. Michael Park, MD, PhD, and Dr. Rohan Lall, MD, at M Health Fairview University of Minnesota Medical Center.

September 14, 2021
(Minneapolis, Minn.) Justin Zenanko, CEO of SynerFuse™, a Minneapolis-based developer of a novel implantable neurostimulator to treat chronic low-back pain without the use of addictive opioids, today announced the addition of Arti Masturzo and Barbara Stinnett as strategic advisors and William Still as vice president of business development and operations to the SynerFuse team.

August 16, 2021
(Minneapolis, Minn.) SynerFuse™ released a two-year global patent search demonstrating that the 12-person Minnesota-based startup is a “Top 10” neuromodulation patent applicant worldwide and the number-one patent applicant for its strategic area of focus combining “neuromodulation” and the “dorsal root ganglion”...

August 9, 2021
(Sugar Land, Texas) According to filings with the U.S. Securities and Exchange Commission, SynerFuse™ is raising $30,000,000.00 in new funding...

August 1, 2021
(London) This article showcases our top picks for the best Minnesota based Therapeutics companies...

July 31, 2021
(London) This article showcases our top picks for the best Minneapolis-based Medical Device companies...

July 30, 2021
(London) This article showcases our top picks for the best Minnesota based Medical Device companies...

June 22, 2021
(Minneapolis, Minn.) Justin Zenanko, CEO and Co-Founder of SynerFuse™, Inc., a Minneapolis-based medical device company, today announced the appointment of Jeff Fritz as Lead Director of the SynerFuse Board of Directors...

May 27, 2021
(Minneapolis, Minn.) SynerFuse™, Inc., a Minneapolis-based medical device company, is pleased to announce the addition of new members to the SynerFuse team, bringing legal, marketing, and executive management experience to the company...

May 24, 2021
(Minneapolis, Minn.) SynerFuse™, Inc., a Minneapolis-based medical device company, is pleased to announce the addition of new strategic advisors to the SynerFuse team, bringing clinical, economic, and executive management experience to the company…

April 27, 2021
(Minneapolis, Minn.) Problem: patients who have lower back surgery are often at risk for getting hooked on addictive opioids after their procedure. Potential solution: Minneapolis-based SynerFuse™ is developing technology combining spinal fusion hardware with an implantable neuromodulation system, a proactive approach to treating a patient’s pain…

Mar 04, 2021, 14:55 ET
(Minneapolis, Minn.) - SynerFuse™, a developer of a novel implantable neurostimulator intended to treat chronic low-back pain without the use of addictive opioids, today announced a strategic development and manufacturing relationship with Cirtec Medical Corporation to support their current investigational and future commercial technology needs…

April 27, 2021
(Minneapolis, Minn.) Justin Zenanko, CEO of SynerFuse™, a Minneapolis-based developer of a novel implantable neurostimulator to treat chronic low-back pain without the use of addictive opioids, today announced the addition of Jeannine Rivet as strategic advisor and Dr. Erika Petersen as a board member…

March 4, 2021
(Minneapolis, Minn.) - SynerFuse™, a developer of a novel implantable neurostimulator intended to treat chronic low-back pain without the use of addictive opioids, today announced a strategic development and manufacturing relationship with Cirtec Medical Corporation to support their current investigational and future commercial technology needs…

November 6, 2018
(St. Paul, Minn.) - “We are assembling a team of people who possess the important qualities of energy, smarts, creativity, and experience to bring our non-opioid, neuromodulation, pain management device to the spinal market ,” said Justin Zenanko, CEO of SynerFuse™. “Private companies, pursuing disruptive medical technologies, will provide important solutions as we move away from the over-use of narcotics in pain management…